Bcma-Cd19 Ccar T Cells
Immunoglobulin G4-Related Sclerosing Disease
Peking University People's HospitalCell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Immunoglobulin G4-Related Sclerosing Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Leflunomide Chinese PLA General Hospital | Phase 4 | BB |
Prednisone Chinese PLA General Hospital | Phase 4 | BB |
Filgotinib UMC Utrecht | Phase 2 | CCC |
Lenalidomide Mayo Clinic | Phase 1 | CC |
Rituximab Mayo Clinic | Phase 1 | CC |
Mtm-H-001 Beijing GoBroad Hospital | N/A | D |
Lvivo-Tavec400 Product Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Early Phase 1 | NR |
Same molecule, other indications
Bcma-Cd19 Ccar T Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →